Definitive Healthcare (DH) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenue grew 5% year-over-year to $63.7 million, with adjusted EBITDA up 21% to $20.9 million (33% margin), both exceeding guidance.

• Net loss widened to $306.2 million, primarily due to a $363.6 million non-cash goodwill impairment charge.

• Enterprise customer count increased by 32 (6%) to 537, while total customer count declined due to higher churn among smaller customers.

• CEO transition to Kevin Coop, who is focusing on operational simplification, platform unification, and direct sales oversight.

• Macroeconomic headwinds and sales execution challenges led to revised guidance and increased customer churn.

Financial highlights

• Revenue: $63.7 million, up 5% year-over-year; adjusted EBITDA: $20.9 million (33% margin), up 21%; adjusted net income: $14.2 million, up 14%.

• Net loss: $(306.2) million, compared to $(11.6) million in Q2 2023, due to goodwill impairment.

• Adjusted gross margin: 83% in Q2 2024, down 260 basis points year-over-year.

• Unlevered free cash flow: $21.5 million in Q2, $78.6 million TTM (up 50% year-over-year).

• Cash and short-term investments: $296 million; debt: $251 million as of June 30, 2024.

Outlook and guidance

• Q3 2024 revenue expected at $61–$62.5 million (down 4–7% year-over-year); adjusted EBITDA margin forecast at 28–31%.

• Full-year 2024 revenue guidance: $247–$251 million (flat to down 2% year-over-year); adjusted EBITDA: $74–$77 million (30–31% margin).

• Margin expansion of 50–100 basis points expected for the year despite top-line pressures.

• Guidance reflects acquisition impacts, bookings shortfall, and ongoing macroeconomic headwinds.